PH12022550798A1 - Pediatric suspension formulation - Google Patents

Pediatric suspension formulation

Info

Publication number
PH12022550798A1
PH12022550798A1 PH1/2022/550798A PH12022550798A PH12022550798A1 PH 12022550798 A1 PH12022550798 A1 PH 12022550798A1 PH 12022550798 A PH12022550798 A PH 12022550798A PH 12022550798 A1 PH12022550798 A1 PH 12022550798A1
Authority
PH
Philippines
Prior art keywords
pharmaceutically acceptable
acceptable salt
ppi
suspension formulation
omeprazole
Prior art date
Application number
PH1/2022/550798A
Other languages
English (en)
Inventor
Maurice Joseph Anthony Clancy
Damien Patrick Flynn
Dennis Mark Mcdaid
Original Assignee
Xeolas Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xeolas Pharmaceuticals Ltd filed Critical Xeolas Pharmaceuticals Ltd
Publication of PH12022550798A1 publication Critical patent/PH12022550798A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00Containers specially adapted for medical or pharmaceutical purposes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14Details; Accessories therefor
    • A61J1/1412Containers with closing means, e.g. caps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1611Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PH1/2022/550798A 2019-10-04 2020-10-02 Pediatric suspension formulation PH12022550798A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962911035P 2019-10-04 2019-10-04
US201962911689P 2019-10-07 2019-10-07
US202063062785P 2020-08-07 2020-08-07
PCT/IB2020/059280 WO2021064682A1 (en) 2019-10-04 2020-10-02 Pediatric suspension formulation

Publications (1)

Publication Number Publication Date
PH12022550798A1 true PH12022550798A1 (en) 2023-09-18

Family

ID=72744602

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2022/550798A PH12022550798A1 (en) 2019-10-04 2020-10-02 Pediatric suspension formulation

Country Status (15)

Country Link
US (2) US11826359B2 (https=)
EP (2) EP4331572A3 (https=)
JP (2) JP7801996B2 (https=)
KR (1) KR20220103711A (https=)
CN (1) CN114929222B (https=)
AU (1) AU2020358472B2 (https=)
CA (1) CA3153555A1 (https=)
ES (1) ES2974364T3 (https=)
IE (1) IE20200221A1 (https=)
IL (1) IL291778B2 (https=)
MX (1) MX2022003917A (https=)
PH (1) PH12022550798A1 (https=)
TW (1) TW202126301A (https=)
WO (1) WO2021064682A1 (https=)
ZA (1) ZA202203563B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202126301A (zh) 2019-10-04 2021-07-16 愛爾蘭商席歐拉斯製藥有限公司 小兒懸浮調配物
GB2631129A (en) * 2023-06-23 2024-12-25 Orbit Pharma Ltd A powder composition for oral suspension of proton pump inhibitors and the method of preparing the same

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
US6645988B2 (en) 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US20020192299A1 (en) 2000-12-28 2002-12-19 Rajneesh Taneja Pharmaceutical compositions of a non-enteric coated proton pump inhibitor with a carbonate salt and bicarbonate salt combination
CA2448997A1 (en) * 2001-05-31 2002-12-05 Microdose Technologies, Inc. Metering and packaging of controlled release medication
US20050220870A1 (en) * 2003-02-20 2005-10-06 Bonnie Hepburn Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
US20050098526A1 (en) * 2003-11-06 2005-05-12 Robertino Catalin Two bottles/containers in one
WO2005076987A2 (en) 2004-02-10 2005-08-25 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory agent
ES2283172B1 (es) * 2005-01-21 2008-08-16 Universidad De Granada Suspension extemporanea de omeprazol para via oral.
AR056062A1 (es) * 2006-06-05 2007-09-19 Bago Sa Labor Composicion farmaceutica antiacida en forma de polvo, preparacion farmaceutica que la comprende y proceso para su preparacion
EP2068854A2 (en) 2006-07-29 2009-06-17 Graceway Pharmaceuticals, LLC Business method to treat and/or prevent a gastric acid disorder with a proton pump inhibitor (ppi) and a cholinergic agonist to induce rapid onset of ppi action with or without food
EP2068841B1 (en) 2006-10-05 2018-09-26 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
JP2011512416A (ja) 2008-02-20 2011-04-21 ザ・キュレイターズ・オブ・ザ・ユニバーシティー・オブ・ミズーリ オメプラゾール及びランソプラゾールの組合せと緩衝剤を含んでなる組成物とそれを使用する方法
JP5248614B2 (ja) 2008-09-01 2013-07-31 株式会社フレッシュ キャップおよびキャップ付き容器
PL2827843T3 (pl) * 2012-03-20 2016-11-30 Sposób wytwarzania dojelitowych alginianowych mikrokapsułek poprzez żelowanie jonowe zawierających diklofenak lub jedną z jego soli oraz zawierającej je wielocząsteczkowej kompozycji farmaceutycznej
GB2513172A (en) 2013-04-18 2014-10-22 Nupharm Lab Ltd Liquid dosage form and delivery system
BR112017001968A2 (pt) 2014-07-30 2017-11-21 Sun Pharmaceutical Ind Ltd embalagem de duas câmaras para uma composição farmacêutica líquida oral de múltiplas doses
CA2984725A1 (en) * 2015-05-01 2016-11-10 Sun Pharmaceutical Industries Limited Dual-chamber pack for extended release suspension compositions
US10238803B2 (en) 2016-05-02 2019-03-26 Sun Pharmaceutical Industries Limited Drug delivery device for pharmaceutical compositions
US11207307B2 (en) 2016-06-16 2021-12-28 Azurity Pharmaceuticals, Inc. Composition and method for proton pump inhibitor suspension
US10137111B2 (en) * 2016-08-11 2018-11-27 Adamis Pharmaceuticals Corporation Drug compositions comprising an anti-parasitic and proton pump inhibitor
TW202126301A (zh) 2019-10-04 2021-07-16 愛爾蘭商席歐拉斯製藥有限公司 小兒懸浮調配物

Also Published As

Publication number Publication date
US11826359B2 (en) 2023-11-28
AU2020358472B2 (en) 2026-01-15
US20230390266A1 (en) 2023-12-07
WO2021064682A1 (en) 2021-04-08
JP7801996B2 (ja) 2026-01-19
IE20200221A1 (en) 2022-08-17
EP4331572A3 (en) 2024-06-05
KR20220103711A (ko) 2022-07-22
CA3153555A1 (en) 2021-04-08
AU2020358472A1 (en) 2022-04-07
CN114929222A (zh) 2022-08-19
JP2025170126A (ja) 2025-11-14
ZA202203563B (en) 2025-07-30
EP4331572A2 (en) 2024-03-06
IL291778A (en) 2022-06-01
ES2974364T3 (es) 2024-06-27
EP3799861A1 (en) 2021-04-07
IL291778B2 (en) 2024-09-01
MX2022003917A (es) 2022-06-14
IL291778B1 (en) 2024-05-01
EP3799861B1 (en) 2023-11-22
US12465600B2 (en) 2025-11-11
US20210100784A1 (en) 2021-04-08
JP2022550690A (ja) 2022-12-05
TW202126301A (zh) 2021-07-16
CN114929222B (zh) 2025-10-28

Similar Documents

Publication Publication Date Title
MX2021000887A (es) Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer.
WO2016004093A3 (en) Therapeutic compositions including galectin-3 inhibitors and uses thereof
MX2021005924A (es) Compuestos y metodos de uso de los mismos para el tratamiento del cancer.
MX2019013954A (es) Inhibidores covalentes de kras.
MX361590B (es) Suministro topico de composiciones para la piel que tienen ph bajo.
WO2016164675A8 (en) Substituted quinazoline compounds and methods of use thereof
WO2015183963A3 (en) Therapeutic compositions including redox-active parabenzoquinones and uses thereof
EP4342540A3 (en) Substituted heterocyclyl derivatives as cdk inhibitors
MX380928B (es) Inhibidores de kras g12c.
EP4684836A3 (en) Combinations of lsd1 inhibitors for use in the treatment of neoplastic diseases
MY183536A (en) Pharmaceutical compositions comprising azd9291
MX2021010106A (es) Inhibidores de la via de respuesta al estres integrada.
MX2022003570A (es) Composiciones de vesícula extracelular.
EP4609912A3 (en) New use of a combination of sacubitril and valsartan
MX2010002735A (es) Envase de titulacion para neramexano y su uso en el tratamiento de un trastorno del oido interno.
MX2020010300A (es) Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas.
ZA202203563B (en) Pediatric suspension formulation
MX2020007971A (es) Composiciones y metodos para tratar edema pulmonar o inflamacion pulmonar.
MX418886B (es) Derivado de pirimidina que inhibe el crecimiento de celulas cancerosas y uso medicinal del mismo
HK1249011A1 (zh) 包括线粒体分裂抑制肽的治疗组合物、其变体及这些的使用方法
MY191261A (en) Novel preparation containing benzimidazole derivative
MA43876B1 (fr) Compositions pharmaceutiques et leur utilisations contre les maladies de surcharge lysosomale
MX2017015202A (es) Formulaciones liquidas de celecoxib para administracion oral.
MX391191B (es) Composiciones de liberación extendida de onapristona y métodos.
WO2015183984A3 (en) Therapeutic compositions including tocopherol and uses thereof